Daiichi Sankyo
Jinali Dhebariya is an accomplished professional in regulatory affairs, currently serving as the Senior Director of Regulatory Affairs CMC and Group Lead at Daiichi Sankyo, Inc. since October 2022. Prior to this role, Jinali held the position of Senior Director of Global CMC Regulatory Affairs at Luzsana Biotechnology from August 2021 to September 2022. At GSK, experience spanned over nearly 14 years, progressing from Senior Scientist to Associate Director, focusing on Biopharm CMC Regulatory Affairs. Earlier career experience includes a role as Research Associate at Genentech Inc./Tanox from July 2004 to November 2007. Jinali holds a Master’s degree in Regulatory Affairs/Quality Assurance from Temple University (2013-2014) and a Bachelor's degree in Biology from the University of Houston (2000-2004).
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.